Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-γ production in patients with cervical cancer

Journal of Immunotherapy

Volumn 30, Issue 5, 2007, Pages 523-532

  Zehbe, Ingeborg ^a   Kaufmann, Andreas M ^b   Schmidt, Markus ^c   Hohn, Hanni ^c   Maeurer, Markus J ^d  

^a THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CD8; HPV; T cells; Tumor

Indexed keywords

CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HLA A ANTIGEN; TETRAMER;

ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MARKER; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INTERFERON PRODUCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TRANSGENICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HLA-A ANTIGENS; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON TYPE II; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; ONCOGENE PROTEINS, VIRAL; RECEPTORS, CHEMOKINE; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 34250838681     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31803240fa     Document Type: Article

References (34)

1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
2. Snyder JT, Alexander-Miller MA, Berzofskyl JA, et al. Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res. 2003;1:287-294.
3. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
4. Bartholomew JS, Stacey SN, Coles B, et al. Identification of a naturally processed HLA A0201-restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein. Eur J Immunol. 1994;12:3175-3179.
5. Santegoets SJ, Schreurs MW, Masterson AJ, et al. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother. 2006;9:1-11.
6. Hu ZB, Minden MD, McCulloch EA. Regulation of the synthesis of bcl-2 protein by growth factors. Leukemia. 1996;10:1925-1940.
7. Quentmeier H, Duschl A, Hu ZB, et al. MUTZ-3, a monocytic model cell line for interleukin-4 and lipopolysaccharide studies. Immunology. 1996;89:606-612.
8. Masterson AJ, Sombroek CC, De Gruijl TD, et al. MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood. 2002;100:701-703.
9. Grignani F, Kinsella T, Mencarelli A, et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 1998;58:14-19.
10. Morgenstern JP. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;12:3587-3589.
11. Kaufmann AM, Gissmann L, Simms P, et al. Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells. Immunobiology. 2000;202:339-352.
12. Jager E, Salter R, Castelli C, et al. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes. J Immunol. 2002;168:2766-2772.
13. Hohn H, Kortsik C, Tully G, et al. Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease activity and cross-reactivity to a peptide from HIVenv gp120. Eur J Immunol. 2003;33:1613-1623.
14. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem. 1998;31:205-262.
15. Kanduc D. Translational regulation of human papillomavirus Type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit β1-globin and human cytokeratin 7. J Virol. 2002;76:7040-7048.
16. Mrass P, Takano H, Guan Ng L, et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med. 2006; (published online November 20th, 2006).
17. Sallusto F, Lenig D, Lipp M, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
18. Bontkes HJ, Ruizendaal JJ, Kramer D, et al. Interleukin-12 increases proliferation and interferon-gamma production but not cytolytic activity of human antigen-specific effector memory cytotoxic T lymphocytes: power of the effect depends on the functional avidity of the T cell and the antigen concentration. Hum Immunol. 2005;66:1137-1145.
19. Hohn H, Pilch H, Gunzel S, et al. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. J Virol. 2000;74:6632-6636.
20. Lurquin C, Lethe B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med. 2005;201:249-257.
21. Kleinheinz A, von Knebel-Doeberitz M, Cripe TP, et al. Human papillomavirus early gene products and maintenance of the transformed state of cervical cancer cells in vitro. Curr Top Microbiol Immunol. 1989;144:175-179.
22. von Knebel-Doeberitz M, Rittmuller C, zur Hausen H, et al. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer. 1992;51:831-834.
23. Drake CG, Doody DH, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239-249.
24. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005;4703:141-146.
25. Ercolini AM, Ladle BH, Manning EZ, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Ex Med. 2005;201:1591-1602.
26. Andersen P, Smedegaard B. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun. 2000;68:621.
27. Bell EB, Sparshott SM, Bunce C. CD4+ T-cell memory, CD45R subsets and the persistence of antigen - a unifying concept. Immunol Today. 1998;19:60-64.
28. Zehbe I, Hohn H, Pilch H, et al. Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance. Int J Cancer. 2005;117:807-815.
29. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
30. Terabe M, Matsui S, Park JM, et al. Transforming growth factorbeta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003;198:1741-1752.
31. Nieland JD, Loviscek K, Kono K, et al. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. J Immunother. 1998;21:317-322.
32. Rodriguez PC, Zea AH, DeSalvo J, et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003;171:1232-1239.
33. Zippelius A, Batard P, Rubio-Godov V, et al. Effector function of human tumor-specific CD8T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004;64:2865-2873.
34. Teague RM, Sather BD, Sacks JA. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med. 2006;12:335-341.